Prokidney (PROK) Short term Debt (2021 - 2022)
Prokidney's (PROK) quarterly Short term Debt came in at $80687.0 in Q2 2022, up 214.66% year-on-year from $25643.0 in Q2 2021, and up 84.96% on a QoQ basis from $43623.0 in Q1 2022.
Prokidney (PROK) Short term Debt (2021 - 2022) Analysis & Trends
Prokidney (PROK) has 2 years of Short term Debt data on file, last reported at $80687.0 in Q2 2022.
- On a quarterly basis, Short term Debt rose 214.66% year-over-year to $80687.0 in Q2 2022; TTM through Jun 2022 was $80687.0, a 214.66% increase from a year earlier, with the FY2021 full-year figure at $10000.0, changed N/A from the prior year.
- Short term Debt for Q2 2022 stood at $80687.0, up from $43623.0 in the prior quarter.
- Over the last five years, Short term Debt for PROK reached as high as $80687.0 in Q2 2022 and fell as low as $10000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Prokidney | 96.00 Mn | 96.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 80,687.00 |
| Mar 31, 2022 | 43,623.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 38,178.00 |
| Jun 30, 2021 | 25,643.00 |